![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H20ClN3O4S |
Molar mass | 421.90 g·mol−1 |
3D model (JSmol) | |
Melting point | 157 to 158 °C (315 to 316 °F) |
| |
| |
![]() ![]() |
W-18 is a compound in a series of 32 substances (named W-1 to W-32) that were first synthesized in academic research on analgesic drug discovery in the 1980s and appeared as a designer drug in the 2010s.
W-18 was invented at the University of Alberta by a lab working on analgesic drug discovery in the 1980s, and preliminary studies in animals showed it had pain-killing activity in mice. [1] [2]
The chemical was detected in connection with recreational drug use as substitute for other controlled substances in Europe in 2013, [3] and in the United States. [4] In Canada, Alberta Law Enforcement Response Teams (ALERT) seized four kilograms of W-18 in a drug bust in Edmonton in December 2015 [5] and W-18 was also detected by Health Canada in at least three of 110 fentanyl tablets seized from a Calgary home in August 2015. [6] [4]
W-18 was commonly reported to be an opioid in the popular press in the 2010s, which was later revealed not to be correct. [7] [8] [9] W-18 was found to obtain weak activity at both sigma receptors and the translocator protein (peripheral benzodiazepine receptor). [9] It also inhibits the hERG potassium channel with micromolar affinity, which could potentially cause cardiac arrhythmia at high doses. [10]